Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology | Nephrology/Urology
Kidney Cancer
Kidney Cancer Disease Study CRAD001L2201
Kidney Cancer Disease Study CRAD001L2201
A Randomized Open Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2A Plus Bevacizumab for the First-Line Treatment of Patients with Metastatic Clear Cell Carcinoma of the Kidney
A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metastatic Clear Cell Carcinoma of the Kidney
Compassionate Treatment of Malignant Neuroendocrine Tumors with Radioactive MIBG
Development of a Blood Test of Anti-IMP3 Autoantibody for the Detection of Renal Cell Carcinoma with Metastasis and Metastatic Potential
Kidney Cancer Disease Study CRAD001L2201
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Kidney Cancer Disease Study CRAD001L2201
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Kidney Cancer Disease Study CRAD001L2201
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Kidney
Kidney Cancer Disease Study CRAD001L2201
Men and Women ages 18 and older with kidney cancer needed for research study.
Kidney Cancer Disease Study CRAD001L2201
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeautic in Subjects with Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination with Sunitinib
